| HOME >> MEDICINE >> TECHNOLOGY |
Session) -- Oral presentation beginning at 4:30 p.m. local time one
Saturday, May 31, 2008.
-- "Effect of prior treatment status on the efficacy and safety of
ipilimumab monotherapy in treatment-naive and previously treated
patients with advanced melanoma" (Abstract #9055, Melanoma
Session) -- Poster presentation from 2:00 p.m. to 6:00 p.m. local time
on Saturday, May 31, 2008.
-- "An analysis of the effectiveness of specific guidelines for the
management of ipilimumab-mediated diarrhea/colitis: prevention of
gastrointestinal perforation and/or colectomy" (Abstract #9063,
Melanoma Session) - Poster presentation from 2:00 p.m. to 6:00 p.m.
local time on Saturday, May 31, 2008.
-- "Model-based evaluation of ipilimumab dosage regimen in patients with
advanced melanoma" (Abstract #9073, Melanoma Session) -- Poster
presentation from 2:00 p.m. to 6:00 p.m. local time on Saturday, May
31, 2008.
-- "Safety and efficacy of ipilimumab with or without prophylactic
budesonide in treatment-naive and previously treated patients with
advanced melanoma" (Abstract #9010, Melanoma Session) -- Oral
presentation beginning at 10:15 a.m. local time on Sunday, June 1,
2008.
-- "Efficacy and safety of ipilimumab induction and maintenance dosing in
patients with advanced melanoma who progressed on one or more prior
therapies" (Abstract #9021, Melanoma Session) -- Poster presentation
and discussion from 2:00 p.m. to 6:00 p.m. local time on Sunday, June
1, 2008.
-- "Disease control and long-term survival in chemotherapy-naive patients
with advanced melanoma treated with ipilimumab (MDX-010) with or
without dacarbazine" (Abstract #9022, Melanoma Session) -- Poster
presentation and discuss
'/>"/>
| SOURCE Medarex, Inc. Copyright©2008 PR Newswire. All rights reserved |